<DOC>
	<DOCNO>NCT00001405</DOCNO>
	<brief_summary>This protocol design study technique need develop gene therapy treatment certain inherit immune system disease . Healthy normal volunteer 18 65 year age patient chronic granulomatous disease ( CGD ) , X-linked severe combine immune deficiency ( X-SCID ) , leukocyte adhesion deficiency ( LAD ) , interferon gamma receptor deficiency ( IGR-deficiency ) inherit disease affect precursor blood cells-bone marrow cell generate blood cells-may eligible study . Patients repeat severe infection possibly due inherit blood cell abnormality may also participate . Candidates screen medical history , physical examination blood test . Patients active infection hospitalize study . Uninfected participant see outpatient NIH Clinical Center . Participants follow procedure : - G-CSF administration All participant daily injection granulocyte-colony stimulating factor ( G-CSF ) . This drug genetically engineer hormone stimulate bone marrow release white blood cell white cell precursor bloodstream . The injection give skin arm leg , use small needle . Patients injection 6 7 day , normal volunteer 5 . A small blood sample drawn day injection monitor white cell count change number blood cell precursor . ( Smaller child child 10 year age may blood drawn alternate day less reduce number needle stick amount blood taken. ) . Larger blood draw take day 6 and/or 7 patient day 5 and/or 6 normal volunteer . - Leukapheresis This procedure collect large number circulate blood precursor cell optional may take place large blood draw describe . Patients 5 year old old may leukapheresis . Whole blood collect needle arm vein . The blood circulates machine separate component . The desired cell remove rest blood return body , either needle second one place arm . The cell obtain used purify blood precursor grow culture examine ability transfer new gene precursor cell . For patient whose arm vein scar needle placement , vein groin area ( femoral vein ) may use instead . - Bone marrow aspiration - This procedure obtain bone marrow sample optional . Normal volunteer agree procedure may undergo aspiration three time . The hip area anesthetize small sample bone marrow draw special needle insert hipbone . The first aspiration do day G-CSF injection start ; second do soon last injection ( day 6 7 ) , third do 7 10 day last injection . - Repeat blood test - At day 6 7 blood test do begin study repeat check blood count liver kidney function . Four month end study , participant ask repeat entire procedure examine effect two cycle G-CSF mobilization individual . This second cycle optional .</brief_summary>
	<brief_title>Use G-CSF Obtain Blood Cell Precursors</brief_title>
	<detailed_description>The goal study obtain CD34+ hematopoietic stem cell ( HSC ) peripheral blood and/or bone marrow , Mononuclear Cells ( lymphocytes monocyte ) , granulocyte ( gran ) peripheral blood . These collection maybe use clinical treatment laboratory research . Participants include : 1 . Patients primary immune deficiency ( PID ) collection clinical use benefit patient ; 2 . Patients primary immune deficiency ( PID ) collection laboratory research use . 3 . Healthy sibling related donor patient PID need allogeneic stem cell transplant direct donation designate patient ; 4 . Healthy adult volunteer . The majority subject HSC collect peripheral blood apheresis . Daily subcutaneous injection G-CSF ( granulocyte colony stimulate factor/filgrastim ) 5 6 day standard method use mobilize HSC peripheral blood prior apheresis , use subject . Plerixafor ( Mozobil ) approve use combination GCSF mobilize HSC use patient , sibling/related donor undergo collection HSC apheresis . Some patient healthy sibling/related donor clinical scale aspiration collection bone marrow obtain HSC clinical use . Some participant may small sample needle aspiration collection bone marrow obtain research purpose . Mononuclear cell and/or Granulocytes ( gran ) collect peripheral blood apheresis follow stimulation , G-CSF alone , combine single dose G-CSF ( 480mcg ) Dexamethasone ( 8mg ) prior collection use Department Transfusion Medicine . HSC , mononuclear cell , gran collection patient PID may use laboratory research may designate future clinical treatment patient separate treatment protocol . HSC collection healthy sibling/related donor patient PID need allogeneic stem cell transplant designate clinical treatment related patient . HSC , mononuclear cell , gran collection healthy volunteer designate entirely laboratory research . HSC use follow three clinical purpose , clinical treatment would occur separate IRB approve protocol : 1 . Autologous HSC patient may genetically modify infused patient treatment infection underlie disease ( Gene therapy ) ; 2 . Autologous HSC patient may serve back ( rescue product ) patient undergo match unrelated donor transplantation haploidential transplantation ; 3 . HSC sibling/related donor may use direct donation allogeneic transplant relate patient . Mononuclear Cells ( lymphocytes monocyte ) granulocyte use follow clinical purpose , 1 . Autologous lymphocyte may genetically modify infused patient treatment infection underlie disease ( Gene therapy ) ; 2 . Autologous lymphocyte , monocyte granulocyte ( neutrophil ) may transfected mRNAs transiently express therapeutic protein treatment infection underlie disease ( Gene therapy ) . HSC , lymphocytes , monocytes granulocyte use laboratory research study include : Delineating pathophysiology inherit immune deficiency ; Delineating physiology improve engraftment hematopoietic stem cell ; Determining hematopoietic stem cell may maintain ex vivo culture without lose pluripotent potential ; Delineating molecular mechanism responsible lineage specific differentiation ; Developing efficient method gene transfer hematopoietic stem cell corrective gene therapy ; Developing method restoration function defective peripheral blood monocyte and/or granulocyte ; Further characterization peripheral blood monocyte and/or granulocytes patient PID .</detailed_description>
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<criteria>ELIGIBILITY CRITERIA : Patients ( Patients genetically define PID clinical history consistent PID ) 1 . Patients genetically define PID clinical history recurrent infection problem suggestive PID , must 270 year age , 2 . Is least 10 kilogram body weight . 3 . Some patient may active bacterial fungal infection time study entry . 4 . Preserved renal function ( creatinine less equal 2.5 mg/dL ; le equal 3+ proteinuria ) ; preserve hepatic function ( bilirubin less equal 2.0 mg/dl ) ; preserve hematologic function ( WBC great equal to1000/mm^3 ; granulocyte great equal 500/mm^3 ; platelet great equal 100,000 ; hematocrit great equal 25 ) . Of note , patient PID often associate chronic thrombocytopenia . Patients stable chronic thrombocytopenia eligible collection , investigator discretion , caveat patient platelet count &lt; 40,000 day prior collection transfuse platelet morning collection . Platelets may also give patient follow collection medically indicated.. 5 . Patients childbearing potential may enter use effective contraception negative serum urine pregnancy test within one week begin GCSF administration . 6 . Patients may remain regimen prophylactic treatment deem necessary investigator . 7 . Willingness allow blood cell sample store 8 . Willingness allow blood and/or bone marrow sample modify iPS cell Healthy Donors ( HLA match sibling related donor patient PID need allogeneic hematopoietic stem cell transplant ) 1 . Healthy sibling relative patient PID need allogeneic transplant , 270 year age , 2 . Is fully closely HLA tissue match patient PID hematopoietic stem cell PBSC bone marrow collection designate clinically benefit , 3 . Is least 10 kilogram body weight . 4 . Normal renal function ( creatinine less equal 1.5 mg/dL ; le equal 1+ proteinuria ) ; normal hepatic function ( bilirubin less equal 1.5 mg/dL ) ; normal hematologic function ( WBC great equal 2500/mm^3 ; granulocyte great equal 1200/mm^3 ; platelet great equal 120,000 ; hematocrit great equal 38 ) . 5 . Normal female donor childbearing potential may enter use effective contraception negative serum urine pregnancy test within one week begin GCSF administration . 6 . Willingness allow blood cell sample store 7 . Willingness allow blood and/or bone marrow sample modify iPS cell Healthy Volunteers 1 . Healthy adult age 1865 without active current infection history recurrent infection , 2 . Weighs least 50kg . 3 . Normal renal function ( creatinine less equal 1.5 mg/dL ; le equal 1+ proteinuria ) ; normal hepatic function ( bilirubin less equal 1.5 mg/dL ) ; normal hematologic function ( WBC great equal 2500/mm^3 ; granulocyte great equal 1200/mm^3 ; platelet great equal 120,000 ; hematocrit great equal 38 ) . 4 . Normal female volunteer childbearing potential may enter use effective contraception negative serum urine pregnancy test within one week begin GCSF administration . 5 . Willingness allow blood cell sample store 6 . Willingness allow blood and/or bone marrow sample modify iPS cell For PBMCs gran collection , adult subject know genetic mutation may participate healthy volunteer research purpose long criterion list fulfil . EXCLUSIONS : Patients 1 . Patients hemodynamically unstable ( systolic diastolic blood pressure fall 20 mm Hg stable patient baseline measurement ) require mechanical respiratory assistance exclude . 2 . Female patient pregnant lactate determined history and/or positive pregnancy test exclude . 3 . Must negative routine blood donor eligibility test criterion include test syphilis ( RPR ) TTV Donor Transplant Panel test ( list modify periodically , may include hepatitis B C , HIV HTLV , T. cruzi ) . This apply leukapheresis patient , test require DTM . 1 . XSCID patient make antibody false positive may occur receive periodic infusion pool donation IVIG . We observe positive antiHBc test patient . If occurs , specific DNA antigen test do must negative . 2 . Autologous HSC Transplant patient may positive Hepatitis B C investigator deem necessary collect used safety backup Healthy Volunteers Healthy Donors 1 . Active bacterial , fungal viral infection evidence history , physical exam ( temperature &gt; 38 degress C ) , WBC &gt; 9000 exclude . 2 . Females pregnant lactating determine history and/or pregnancy test exclude . 3 . Must negative routine blood donor eligibility test criterion , include test syphilis ( RPR ) TTV Recipient Transplant Panel ( list modify periodically , may include hepatitis B C , HIV HTLV , T. cruzi ) This apply leukaphersis patient , test require DTM policy . 4 . Someone without peripheral venous access arm vein adequate apheresis ( healthy volunteer ) . 5 . If opinion investigator participation study place healthy volunteer donor undue risk . Patients Healthy Donors consider clinical scale bone marrow harvest 1. Who unable lie prone bone marrow harvest procedure . 2. Who unable tolerate general anesthesia bone marrow harvest procedure .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 24, 2017</verification_date>
	<keyword>Chronic Granulomatous Disease</keyword>
	<keyword>Apheresis</keyword>
	<keyword>CD34 Cells</keyword>
	<keyword>Infection</keyword>
	<keyword>Nadph Oxidase</keyword>
	<keyword>Normal Volunteer</keyword>
</DOC>